nn777 pinakamalaking
By AAMER MADHANI, Associated Press WASHINGTON (AP) — A top White House official on Wednesday said at least eight U.S. telecom firms and dozens of nations have been impacted by a Chinese hacking campaign. Deputy national security adviser Anne Neuberger offered new details about the breadth of the sprawling Chinese hacking campaign that gave officials in Beijing access to private texts and phone conversations of an unknown number of Americans. Neuberger divulged the scope of the hack a day after the FBI and the Cybersecurity and Infrastructure Security Agency issued guidance intended to help root out the hackers and prevent similar cyberespionage in the future. White House officials cautioned that a number of telecommunication firms and countries impacted could still grow. Related Articles The U.S. believes that the hackers were able to gain access to communications of senior U.S. government officials and prominent political figures through the hack, Neuberger said. “We don’t believe any classified communications has been compromised,” Neuberger added during a call with reporters. She added that Biden has been briefed on the findings and that the White House “has made it a priority for the federal government to do everything it can to get to the bottom this.” The Chinese embassy in Washington on Tuesday rejected the accusations that it was responsible for the hack after the U.S. federal authorities issued new guidance. “The U.S. needs to stop its own cyberattacks against other countries and refrain from using cyber security to smear and slander China,” embassy spokesperson Liu Pengyu said. The embassy did not immediately respond to messages on Wednesday. Associated Press writer David Klepper contributed reporting.Maria Diaz/ZDNET What's the deal? The Mammotion Luba 2 3000H has been mowing my lawn weekly like a well-oiled machine since July, which makes the current $350 Black Friday discount even better. Also: The best Black Friday deals live now ZDNET's key takeaways The Mammotion Luba 2 3000H Built to handle uneven terrain, the Luba 2 is an all-wheel-drive (AWD) robot mower with a GPS-powered perimeter that is surprisingly easy to set up. Despite its mostly consistent performance, the Luba 2 veered off the map a few times during testing. Also, the Mammotion app is not very user-friendly. Mowing the lawn is one of my favorite chores. It lets me focus on an uninterrupted task that satisfies my OCD, with the bonus of completing my exercise ring on my Apple Watch. But even though it's a chore I enjoy, it still steals a couple of hours away from my all-too-short weekend. Also: The best robot mowers of 2024 That's where the Mammotion Luba 2 comes in. Imagine the scene: you take the dog out for a walk and come home to a perfectly mowed lawn despite it being an overgrown mess just an hour before. While you were gone, the robot mower took care of the unruly grass and left a beautiful checkered pattern in its wake. I'm happy to say that this dream became a reality with the Luba 2, and although it has its quirks, it handles the chore of lawn mowing with efficiency and ease. When I received the Mammotion Luba 2 for review, the only wire-free GPS robot mower I'd previously used was the EcoFlow Blade. As you can read in that review, setting up the Blade was dreadful. It occupied hours of my Sunday afternoon, resulting in bickering between my husband and me and repeated explanations to the kids that no, we won't be riding the robot around the yard. This time, setting up the mower fell to my husband on a day when I wasn't home. I planned on helping him with the setup upon my return, but I was pleasantly surprised to find it all done when I returned. In fact, he had nothing... Maria Diaz
WALTHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective December 1, 2024, the company granted non-qualified stock options to purchase 8,400 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $1.09 per share, which is equal to the closing price of the company’s common stock on November 29, 2024. Each stock option will have a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying each stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date. The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecifics and immune cell engagers. Learn more by visiting www.xiliotx.com and follow us on LinkedIn ( Xilio Therapeutics, Inc .). This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. Investor and Media Contact: Scott Young Vice President, Investor Relations and Corporate Communications investors@xiliotx.comNone
White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign
‘Miracle’ mother who survived traumatic birth meets crucial blood donor team
China's ban on key high-tech materials could have broad impact on industries, economy
At now-President-elect Donald Trump’s 2024 campaign rallies, attendees would hold “Trump Will Fix It” signs. Here’s hoping the antitrust policy that President Joe Biden excessively politicized is one of those “its.” Trump’s running mate, Sen. JD Vance, previously said he believes that Biden’s appointee as chair of the Federal Trade Commission, Lina Khan, has done a good job with antitrust policy. I disagree. For nearly 40 years, most antitrust scholars sensibly agreed that the government should base its treatment of potential corporate monopolization, mergers and related issues on these actions’ effect on “consumer welfare.” This standard ensures that antitrust is used only to prevent businesses from undermining economic competition, preserving a market that drives prices down and product quality up on behalf of us consumers. Antitrust should not protect businesses (SET ITAL) from (END ITAL) competition. Upon taking control of the FTC, Khan discarded this standard and, along with it, decades of bipartisan agreement. Biden’s Department of Justice and FTC quickly morphed antitrust into a tool for helping the White House achieve political aims that have nothing to do with keeping markets competitive. Consider, for example, how the FTC pursued Elon Musk. A newly released report by the House Judiciary Committee delved into how Khan issued a consent decree against X (then Twitter) for no reason other than that Musk — whose existing business interests were in other industries — was the company’s CEO. Khan “called for an immediate vote” just days after reporters announced the sale, which an FTC insider confirmed was what triggered the attention. The Biden FTC also had no problem targeting companies that challenged its corporate donor base. For example, Khan released an interim report against pharmacy benefit managers, companies that health plans hire to ensure they are receiving drugs at competitive costs. The major drug manufacturers have spent significant sums lobbying the government to challenge PBMs, even though the government’s own research shows these companies save patients (and taxpayers) significant sums. With the consumer welfare standard diminished, the facts didn’t stop Khan from protecting drug companies, which have showered her boss with campaign contributions, from market discipline. The shenanigans led Melissa Holyoak, a Republican FTC commissioner, to publicly dissent. She protested that “the Report was plagued by process irregularities and concerns over substance — or lack thereof — of the original order.” So much so that “the politicized nature of the process appears to have led to the departure of at least one senior leader at the Commission.” If that’s a “good job” in Vance’s view, we should be alarmed. The Biden DOJ hasn’t acted any more responsibly. For example, it sued RealPage, an AI-based software company that helps landlords come to terms with market pricing for their units, for facilitating alleged price-gouging even though it had no evidence. The Wall Street Journal editorial board stated that “it doesn’t require a Ph.D. in economics to understand that ballooning rents are caused by demand exceeding supply” and that “what’s really going on (with this suit) is an attempt to distract voters from frustration over the Biden Administration’s inflationary policies.” More recently, Biden’s DOJ targeted Visa’s debit card business over market share concerns despite the clear consumer benefits created by the company. These include secure, accessible services that millions of Americans rely on. Businesses and consumers have plenty of payment choices, but millions choose Visa for this reason. Rather than respecting those choices, Biden’s DOJ is pursuing its anti-corporate agenda with little regard for consumers’ welfare. Related Articles Opinion Columnists | Where do Democrats go from here? Opinion Columnists | California’s political clout will fade as long as population growth remains slow Opinion Columnists | Susan Shelley: Slow counts show election system needs reform Opinion Columnists | Here’s to hoping Trump delivers on some of his Libertarian promises Opinion Columnists | Grand DOGE promises of massive cuts to the federal government are unlikely to materialize The solution to the DOJ and FTC’s descent into political partisanship is straightforward: comprehensive reform. Come January, the Trump administration and Republican-controlled Congress must demand a recommitment to the consumer welfare standard. They must institute checks that prevent the DOJ and FTC from waging ideological warfare. Measures to ensure transparency and inter-commission collaboration, such as requiring the FTC to disclose the rationale and goals of its investigations, could also prove helpful. It’s hard to overstate the importance of appointing a better attorney general and FTC chair this time around. Coupled with new oversight measures, it could go far toward restoring fairness, protecting actual competition, and preventing rogue bureaucrats from imposing their will for personal or ideological gain. Most importantly, it would help restore the country’s trust in its governmental institutions. Whether that will come to pass remains to be seen. American businesses and consumers deserve a government that respects the rule of law. By simply refocusing the FTC and antitrust division of the DOJ on their foundational purposes, we can begin a new era of fair and impartial regulation that serves the public good. That’s something we all should be able to get behind. Veronique de Rugy is the George Gibbs Chair in Political Economy and a senior research fellow at the Mercatus Center at George Mason University.
Overhauls of 'heritage brands' raise the question: How important are our products to our identities?